Lineage Cell Therapeutics (LCTX) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 74.5% versus a loss of 45.2%. Over five years, LCTX leads with a -59.7% price change compared with -92.3% for STRO. Sutro Biopharma is the larger company by market cap ($243.1 million vs $239.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | STRO |
|---|---|---|
| Share price | $0.9476 | $14.66 |
| Market cap | $239.66M | $243.08M |
| 1-day change | +1.03% | +1.45% |
| YTD return | -43.26% | +26.71% |
| 1-year return | -45.23% | +74.52% |
| 5-year return | -59.68% | -92.28% |
| EPS (TTM) | $-0.19 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $43.85 |
| 52-week low | $0.88 | $7.15 |
| Distance from 52-week high | -54.66% | -66.57% |
| Average volume | 1.15M | 289.73K |
| Shares outstanding | 252.91M | 16.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed LCTX by 119.7 percentage points over the past year.
LCTX vs STRO FAQ
Which is bigger, Lineage Cell Therapeutics or Sutro Biopharma?
Sutro Biopharma (STRO) is larger, with a market capitalization of $243.08M compared with $239.66M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, LCTX or STRO?
STRO returned +74.52% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.